A cost-effectiveness analysis of prenatal carrier screening for cystic fibrosis

Obstetrics and Gynecology

Volumn 91, Issue 4, 1998, Pages 529-534

  Vintzileos, Anthony M ^a   Ananth, Cande V ^b   Smulian, John C ^a,b   Fisher, Allan J ^a   Day Salvatore, Debra ^c   Beazoglou, Tryfon ^d  

^a Division of Maternal Fetal Medicine   (United States)

^b Ctr for Perinatal Hlth Initiatives   (United States)

^c Division of Clinical Genetics   (United States)

^d UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUTOSOMAL RECESSIVE DISORDER; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DISEASE CARRIER; ECONOMIC ASPECT; GENE MUTATION; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; SCREENING TEST; THERAPEUTIC ABORTION;

COST SAVINGS; COST-BENEFIT ANALYSIS; CYSTIC FIBROSIS; FEMALE; GENETIC SCREENING; HETEROZYGOTE DETECTION; HUMANS; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 0032053665     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(98)00035-0     Document Type: Article

References (17)

1. Nishimi RY. Cystic fibrosis and DNA tests - The implications of carrier screening. JAMA. 269:1993;1921.
2. United States Congress. Office of Technology Assessment. Cystic fibrosis and DNA tests: Implications of carrier screening. Washington, DC: U.S. Government Printing Office, August 1992;215-6.
3. Doksum T, Bernhardt BA. Population-based carrier screening for cystic fibrosis. Clin Obstet Gynecol. 39:1996;763-771.
4. NIH Consensus Statement Online. Genetic testing for cystic fibrosis. 1997, April 14-16; 15(4); in press.
5. Wilfond BS, Nolan K. National policy development for the clinical application of genetic diagnostic technologies Lessons from cystic fibrosis . JAMA. 270:1993;2948-2954.
6. Lieu TA, Watson SE, Washington AE. The cost-effectiveness of prenatal carrier screening for cystic fibrosis. Obstet Gynecol. 84:1994;903-912.
7. Tambor ES, Bernhart BA, Chase GA, Faden RR, Geller G, Hofman KJ, et al. Offering cystic fibrosis carrier screening to an HMO population Factors associated with utilization . Am J Hum Genet. 55:1994;626-637.
8. Clayton EW, Hannig VL, Pfotenhauer JP, Parker RA, Campbell PW 3rd, Phillips JA 3rd. Lack of interest by nonpregnant couples in population-based cystic fibrosis carrier screening. Am J Hum Genet. 58:1996;617-627.
9. Loader S, Caldwell P, Kozyra A, Levenkron JC, Boehm CD, Kazazian HH Jr, et al. Cystic fibrosis carrier population screening in the primary care setting. Am J Hum Genet. 59:1990;234-247.
10. Asch DA, Patton JP, Hershey JC, Mennuti MT. Reporting the results of cystic fibrosis carrier screening. Am J Obstet Gynecol. 168:1993;1-6.
11. Ventura SJ, Martin JA, Mathews TJ, Clarke SC. Advance report of final natality statistics, 1994. Monthly Vital Stat Rep. 44:(11):1996;1-87.
12. Wasserman Y. Physicians' fee reference 1997. 14th ed. 1997;Medical Publishers, Ltd. West Allis, Wisconsin.
13. U.S. Bureau of the Census. Statistical abstract of the United States: 1993. 113th ed. Washington, DC, 1993.
14. Mennie ME, Gilfillan A, Compton M, Curtis L, Liston WA, Pullen I, et al. Prenatal screening for cystic fibrosis. Lancet. 340:1992;214-216.
15. Cunningham FG, MacDonald PC, Gant NF, Leveno KJ, Gilstrap LC III, Hankins GDV, et al. Williams obstetrics. 20th ed. 1997;Appleton & Lange, Stamford, Connecticut.
16. Kerem BS, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, et al. Identification of the cystic fibrosis gene Genetic analysis . Science. 245:1989;1073-1080.
17. Statement of the American Society of Human Genetics on cystic fibrosis carrier screening. Am J Hum Genet. 51:1992;1443-1444.